5.5-Diphenyl-trans-2.4-pentadien-saeure | 19625-92-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5.5-Diphenyl-trans-2.4-pentadien-saeure
• 英文别名: 5,5-Diphenylpenta-2,4-dienoic acid
• CAS: 19625-92-4
• 化学式: C₁₇H₁₄O₂
• 分子量: 250.297
• InChiKey: VTMOVDSOOWNIBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5.5-Diphenyl-trans-2.4-pentadien-saeure 在 palladium-carbon 氢气 、 甲醇 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 5,5-diphenylpentanoic acid
  参考文献：
  名称：

  Benzofuran derivatives and pharmaceutical compositions containing the same

  摘要：

  式(I)所表示的苯并呋喃衍生物或其盐：1（其中R1表示苯基或氢原子；k为0或1；m、n、o、p和q中的每一个是0至5的整数；R2和R3中的每一个表示氢原子或羟基，或R2和R3一起表示氧原子，但k、q和m，或n、o和p不能同时为0）。这些化合物可以抑制STAT 6的磷酸化，并可用于治疗或预防过敏性疾病。

  公开号：

  US20040053940A1
• 作为产物：
  描述：

  二苯甲酮 、 4-溴巴豆酸甲酯 生成 5.5-Diphenyl-trans-2.4-pentadien-saeure
  参考文献：
  名称：

  5,5-二芳基戊-2,4-二烯酰胺作为潜在的抗疟药。

  摘要：

  DOI：

  10.1021/jm00310a604

文献信息

• Carbamic acid compounds comprising an amide linkage as hdac inhibitors
  申请人：——

  公开号：US20040092598A1

  公开（公告）日：2004-05-13

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)—and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  这项发明涉及抑制HDAC活性的某些活性碳酸酰胺化合物，其化学式为（1），其中：A是芳基；Q1是至少有2个碳原子骨架的芳基前导基团；J是选择自以下的酰胺键：—NR1C(═O)—和—C(═O)NR1—；R1是酰胺取代基；Q2是酸前导基团；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的药物组合物，以及在体外和体内使用这种化合物和组合物来抑制HDAC，例如，抑制增殖性疾病，如癌症和牛皮癣。
• PENTADIENAMIDE DERIVATIVE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2050734A1

  公开（公告）日：2009-04-22

  The present invention provides a pentadienamide derivative represented by the formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like; R3 represents a hydrogen atom or is combined together with R4 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; R4 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like, or is combined together with R3 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; and R5, R6, and R7 may be the same or different, and each represents a hydrogen atom or methyl) or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种由式(I)表示的戊二烯酰胺衍生物:(其中R1代表取代或未取代的芳基或取代或未取代的芳香族杂环基；R2代表取代或未取代的芳基、取代或未取代的芳香族杂环基、取代或未取代的杂环螺环基或类似物；R3代表氢原子或与R4及其相邻的氮原子结合形成取代或未取代的杂环基；R4代表取代或未取代的芳基、取代或未取代的芳香族杂环基、取代或未取代的杂环螺环基或类似物，或与R3及其相邻的氮原子结合形成取代或未取代的杂环基；R5、R6和R7可以相同也可以不同，每个代表氢原子或甲基)或其药学上可接受的盐等。
• ARYL ALKENAMIDES DERIVATIVES AS MCP-1 ANTAGONISTS
  申请人：——

  公开号：US20020028833A1

  公开（公告）日：2002-03-07

  Aryl alkenamides derivatives of Formula I or a pharmaceutically acceptable salt thereof are novel MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection 1 V=O, S, NH or a bond; Ar can be unsubstituted or substituted benzimidazole, phenyl, biphenyl, pyridyl, naphthyl, quinoline, isoquinoline or indole; n=2-6; m=1-3; X=O (oxygen), S (sulfur), ═CH 2 , ═NH or H 2 ; R 1 and R 2 can independently be hydrogen, lower alkyl of from 1-4 carbon atoms, —(CH 2 ) n OR 6 , —(CH 2 ) n NR 3 R 4 , —(CH 2 ) n ′CONR 3 R 4 , —(CH 2 ) n ′COOR 6 , —(CH 2 ) r Ar′, where n′=0-6 r=0-4 R 3 and R 4 can independently be hydrogen, lower alkyl of from 1-4 carbon atoms, —(CH 2 ) n OR 6 , or —(CH 2 ) m —Ar′, which can be unsubstituted or substituted with up to 3 substitutents, where “Ar′” is phenyl, pyridyl, or indole; R 3 and R 4 may also be taken together to form a cyclic ring of 3-8 atoms which may also contain oxygen or the group NR 5 where R 5 can be hydrogen, lower alkyl of from 1-4 carbon atoms, cycloalkyl of from 5-12 carbon atoms, or —(CH 2 ) m -Phenyl, which can be unsubstituted or substituted with up to 3 substitutents; R 6 can be hydrogen, lower alkyl or (CH 2 ) m -Phenyl; m=1-3; R 1 and R 2 may be also taken together to form a ring of 3-8 atoms which may also contain oxygen or the group NR 5 , which ring may be substituted on one or more carbon atoms with the group NR 3 R 4 ; the subtituents are defined as: halogen, nitro, CF 3 , alkyl of from 1-12 carbon atoms; —(CH 2 ) r OR 6 —(CH 2 ) r NR 3 R 4 —(CH 2 ) r CONR 3 R 4 —(CH 2 ) r C(O)OR 6 or —(CH 2 ) r SO 2 —OR 6 ; R 7 , R 8 , R 9 and R 10 can each independently be hydrogen, lower alkyl or aryl; and R 7 and R 8 or R 9 and R 10 or X or R 2 when taken together can form a 5-7 membered ring including cycloalkyl, cycloalkenyl, aryl, or heteroaryl containing nitrogen, oxygen or sulfur.

  公式I的芳基烯酰胺衍生物或其药学上可接受的盐是新型MCP-1拮抗剂，因此在治疗炎症、动脉粥样硬化、再狭窄和免疫紊乱，如关节炎和移植排斥方面有用。其中，V=O，S，NH或键；Ar可以是未取代或取代苯并咪唑、苯基、联苯基、吡啶基、萘基、喹啉、异喹啉或吲哚；n=2-6；m=1-3；X=O（氧）、S（硫）、═CH2、═NH或H2；R1和R2可以独立地是氢、1-4碳原子的低烷基、—（CH2）nOR6、—（CH2）nNR3R4、—（CH2）n′CONR3R4、—（CH2）n′COOR6、—（CH2）rAr′，其中n=0-6，r=0-4；R3和R4可以独立地是氢、1-4碳原子的低烷基、—（CH2）nOR6或—（CH2）m—Ar′，其中“Ar′”可以是未取代或取代的苯基、吡啶基或吲哚，最多可以带有3个取代基；R3和R4也可以结合成为3-8个原子的环，该环也可以包含氧或基团NR5，其中R5可以是氢、1-4碳原子的低烷基、5-12碳原子的环烷基或—（CH2）m-苯基，最多可以带有3个取代基；R6可以是氢、低烷基或（CH2）m-苯基；m=1-3；R1和R2也可以结合成为3-8个原子的环，该环也可以包含氧或基团NR5，在其中一个或多个碳原子上取代基团NR3R4；取代基团的定义为：卤素、硝基、CF3、1-12碳原子的烷基；—（CH2）rOR6、—（CH2）rNR3R4、—（CH2）rCONR3R4、—（CH2）rC（O）OR6或—（CH2）rSO2—OR6；R7、R8、R9和R10可以各自独立地是氢、低烷基或芳基；当R7和R8或R9和R10或X或R2结合在一起时，可以形成一个包含氮、氧或硫的5-7个成员的环，包括环烷基、环烯基、芳基或杂芳基。
• PENTADIENAMIDE DERIVATIVES
  申请人：NAKASATO Yoshisuke

  公开号：US20090203667A1

  公开（公告）日：2009-08-13

  The present invention provides a pentadienamide derivative represented by the formula (I): (wherein R 1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like; R 3 represents a hydrogen atom or is combined together with R 4 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; R 4 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like, or is combined together with R 3 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; and R 5 , R 6 , and R 7 may be the same or different, and each represents a hydrogen atom or methyl) or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种由以下公式（I）表示的五二烯酰胺衍生物：（其中，R1代表取代或未取代的芳基或取代或未取代的芳香杂环基；R2代表取代或未取代的芳基，取代或未取代的芳香杂环基，取代或未取代的杂环螺环基或类似物；R3代表氢原子或与R4及其相邻的氮原子结合形成取代或未取代的杂环基；R4代表取代或未取代的芳基，取代或未取代的芳香杂环基，取代或未取代的杂环螺环基或类似物，或与R3及其相邻的氮原子结合形成取代或未取代的杂环基；R5、R6和R7可以相同也可以不同，每个代表氢原子或甲基）或其药学上可接受的盐等。
• 3,5-Dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents
  申请人：PFIZER INC.

  公开号：EP0312269A2

  公开（公告）日：1989-04-19

  A compound for use in lowering blood cholesterol having the relative stereochemical formula:- wherein R is hydrogen, (C₁-C₃)alkyl, phenyl, benzyl or a conventional radical forming an ester group which is hydrolyzable under physiological conditions; R¹ and R², when taken separately, and R₃ are each independently hydrogen, (C₁-C₃)alkyl, benzyl, naphthyl, phenyl or phenyl mono or disubstituted with the same or different substituents selected from the group consisting of F, Cl, Br, I, (C₁-C₃)alkyl, CF₃, (C₁-C₃)alkoxy, benzyl and phenyl; with the proviso that at least one of R¹ and R² is other than hydrogen or (C₁-C₃)alkyl; and R¹ and R², when taken together, are combined with the double bonded carbon atom which they are attached to form a diradical ylidene group of the formula wherein n is 0 or 1 and Y is oxygen, OCH₂, sulfur, SCH₂, methylene or ethylene; or a pharmaceutically acceptable cationic salt thereof when R is hydrogen.

  一种用于降低血液胆固醇的化合物，其相对立体化学式为 其中 R 是氢、(C₁-C₃)烷基、苯基、苄基或形成在生理条件下可水解的酯基的常规基团； R¹和 R² 分别独立地为氢、(C₁-C₃)烷基、苄基、萘基、苯基或苯基单胞、苯基或被选自 F、Cl、Br、I、(C₁-C₃)烷基、CF₃、(C₁-C₃)烷氧基、苄基和苯基的相同或不同取代基单取代或二取代的苯基；但 R¹ 和 R² 中至少有一个不是氢或 (C₁-C₃)烷基；以及 当 R¹ 和 R² 结合在一起时，与它们所连接的双键碳原子结合形成式中的二叉亚 乙基 其中 n 为 0 或 1，Y 为氧、OCH₂、硫、SCH₂、亚甲基或亚乙基；或 当 R 为氢时，其药学上可接受的阳离子盐。